Insider Purchases: Inside the Buy
Tag: featured-insiders
CEO Buys Shares of International Paper: Toilet, Shredded, or Stationery?
International Paper is mid-divorce, mid-restructuring — and its CEO just bought $2M of stock. A messy, event-driven value play with real risk and real conviction.
CEO Purchases Abbott Shares, But the Stock Carries Risks
Abbott’s CEO just stepped in with a $2M insider buy — analysts are bullish, shorts are scarce, and institutions remain locked in. Tempting? Yes. Risk-free? Not quite.
CEO and COO Buy Shares of RLI — Exceptionally Run Insurer, but Not Without Storm Clouds
RLI Corp is exceptionally well run, with insider buying and 30 years of underwriting profits — but forward valuation and catastrophe risk argue for patience, not haste.
CEO Buys More of This Warren Buffett Favorite: Ally Financial Is Up 30% Since Our Bullish Call — Buy More?
Ally Financial is up nearly 30% since our bullish call — and the CEO just bought almost $1M more stock. With Buffett still onboard, analysts bullish, and valuation cheap, this value story may not be done.
Ryan Cohen Buys More GameStop; Time to Play — or Make This Story Short?
Ryan Cohen doubles down on GameStop. Shorts stay crowded. Analysts stay bearish. But profits, cash, and conviction are back. Is GME still a meme — or a mispriced turnaround? 🎯🎮
Insider Buys Shares of Mainz Biomed: Promising Science, Precarious Finances
Mainz Biomed’s cancer-screening science is compelling — and an insider just bought big. But with heavy losses, dilution risk, and a going-concern warning, MYNZ is a biotech moonshot best approached with extreme caution.
Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?
NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.
Key Director Buys United Natural Foods — Are UNFI Shares No Longer “Unfit” for Your Portfolio?
A key director steps in. Institutions already dominate ownership. Valuation looks compressed. United Natural Foods may not be flashy — but the risk/reward is getting interesting.
Insider Buys AAON’s Cool Air and Open Windows: Should You Be a Fan?
AAON is cooling data centers — and heating up investor debate. With insider buying, record backlog, and AI-driven demand tailwinds, the business looks strong. The stock? Still pricey. Let’s break it down — helmet on. ❄️🪖
Insiders Buy Mercer’s Stock, But Who Will Have Mercy on MERC?
Insiders are buying Mercer International (MERC), valuation screens look broken, and shorts are circling. Cheap stock — or classic value trap? 🌲📉